Author: Davis, Joshua S; Ferreira, David; Denholm, Justin T; Tong, Steven YC
Title: Clinical trials for the prevention and treatment of COVIDâ€19: current state of play Cord-id: 6wszpqvx Document date: 2020_6_27
ID: 6wszpqvx
Snippet: Since coronavirus disease 2019 (COVIDâ€19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 randomised controlled trials. Such rapid development and launch of clinical trials is impressive but presents challenges, including the potential for duplication and competition. There is currently no known effective treatment for COVIDâ€19. In order to focus on those studies m
Document: Since coronavirus disease 2019 (COVIDâ€19) emerged in Wuhan, China in December 2019 and spread around the world, over 1100 clinical studies have been registered globally on clinical trials registries, including over 500 randomised controlled trials. Such rapid development and launch of clinical trials is impressive but presents challenges, including the potential for duplication and competition. There is currently no known effective treatment for COVIDâ€19. In order to focus on those studies most likely to influence clinical practice, we summarise the 31 currently registered randomised trials with a target sample size of at least 1000 participants. We have grouped these trials into four categories: prophylaxis; treatment of outpatients with mild COVIDâ€19; treatment of hospitalised patients with moderate COVIDâ€19; and treatment of hospitalised patients with moderate or severe disease. The most common therapeutic agent being trialled currently is hydroxychloroquine (24 trials with potential sample size of over 25 000 participants), followed by lopinavir–ritonavir (seven trials) and remdesevir (five trials). There are many candidate drugs in preâ€clinical and early phase development, and these form a pipeline for future large clinical trials if current candidate therapies prove ineffective or unsafe.
Search related documents:
Co phrase search for related documents- achieve easy and long short: 1
- achieve easy and long short term: 1
- activity limitation and acute respiratory syndrome: 1, 2
- activity limitation and long short: 1, 2
- activity limitation and long short term: 1, 2
- acute respiratory syndrome and adaptive platform trial: 1, 2
- acute respiratory syndrome and adaptive trial design: 1
- acute respiratory syndrome and long short: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and long short term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lopinavir hydroxychloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- adaptive trial design and lopinavir hydroxychloroquine: 1
- long short and lung inflammation: 1, 2, 3, 4, 5
- long short term and lung inflammation: 1, 2, 3
- lopinavir hydroxychloroquine and lung inflammation: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date